Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer

Medicilon, a leading preclinical contract research organization (CRO), has named Dr. Lilly Xu as its new Chief Technology Officer (CTO). With over 30 years of experience in preclinical drug development, Dr. Xu will lead Medicilon's technological innovation and global expansion, strengthening its capabilities to deliver cutting-edge R&D solutions.

Dr. Lilly Xu Chief Technology Officer of Medicilon

Dr. Xu, who holds a Ph.D. in Biology from St Louis University, is a recognized expert in pharmacokinetics, toxicology, and drug metabolism. She has successfully led numerous global drug development programs from early discovery through clinical stages and held leadership roles at major pharmaceutical and biotech companies, including Pharmaron, Icagen, Purdue Pharma, Sanofi, and Amgen.

Dr. Lilly Xu Chief Technology Officer of Medicilon

Dr. Xu added, " I'm honored to join Medicilon’s forward-thinking team. I look forward to contributing to platform innovation, accelerating the transition of research into clinical breakthroughs, and achieving milestones that will benefit our global clients and their patients."

Dr. Chunlin Chen Founder and CEO of Medicilon

Dr. Chen added, " We are thrilled to welcome Dr. Xu during this pivotal time in Medicilon's growth. Her extensive expertise and global perspective align with our vision of driving innovation and advancing our international presence.”

About Medicilon

From its inception in 2004, Shanghai Medicilon Inc. (stock code: 688202.SH) has been committed to providing comprehensive R&D services to pharmaceutical companies, research institutions, and any organizations working in the preclinical space. By the end of June 2024, Medicilon has provided drug development services to over 2,000 clients worldwide, and has been involved in the research and development of 490 new drugs and generic drug projects that have been approved for clinical trials with IND applications.